[Plasminogen activator inhibitor (PAI-1) and markers of endothelial dysfunction in patients with diabetes mellitus].
The authors examined 25 patients with diabetes mellitus type 2 (NIDDM) without vascular complications, treated by sulphonyl urea preparations, 12 hyperinsulinaemic (HI) non-diabetic subjects and 11 normoinsulinaemic healthy subject s. Patients with NIDDM and HI non-diabetics had significantly elevated PAI-1 levels which correlated with the C-peptide level (r = 0.519, p < 0.001), triacylglycerols (TG) (r = 0.685, p < 0.001), BMI (r = 0.607, p < 0.001) and levels of endothelial markers such as von Willebrand s factor and thrombomodulin (TM). In the group of patients with NIDDM no relationship of PAI-1 and C-peptide was found and a significant correlation was found with TM levels (r = 0.609, p = 0.001) and TG levels (r = 0.476, p = 0.046). The results suggest that the endothelial department has an effect on the regulation of PAI-1 levels in patients with NIDDM.
Galajda
P
P
I. interná klinika, MFN Martin.
Martinka
E
E
Baláz
D
D
Stasko
J
J
Kerný
J
J
Planková
E
E
Mokán
M
M
Kubisz
P
P
D000328:Adult; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000503:physiopathology*; D006801:Humans; D006946:Hyperinsulinism / Q000097:blood / Q000503:physiopathology; D008875:Middle Aged; D017396:Plasminogen Activator Inhibitor 2 / Q000097:blood*; D018180:Thrombomodulin / Q000097:blood; D010959:Tissue Plasminogen Activator / Q000097:blood; D014841:von Willebrand Factor / Q000032:analysis
D017396:Plasminogen Activator Inhibitor 2; D018180:Thrombomodulin; D014841:von Willebrand Factor; D010959:Tissue Plasminogen Activator
Inhibítor aktivátora plazminogénu (PAI-1) a markery dysfunkcie endotelu u chorých s diabetes mellitus.